Bronchial carcinoma: Added benefit of crizotinib for first-line treatment not proven
Friday, April 8, 2016 - 18:13
in Health & Medicine
In the only study of direct comparison, carboplatin in the control arm was not used in compliance with the Pharmaceutical Directive, reviewers report.